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Background: Aspirin enhances food allergy symptoms by increasing absorption of ingested allergens. The
objective of this study is to elucidate the role of aspirin in facilitating intestinal absorption of the wheat
allergen, gliadin, in rats.
Methods: Plasma concentrations of gliadin were determined after oral administration by gavage or
administration into a closed intestinal loop in rats. We used an in situ intestinal re-circulating perfusion
experiment to examine the effect of pepsin on aspirin-facilitated gliadin absorption. Fluorescein iso-
thiocyanate (FITC)-labeled dextran-40 (FD-40) was used as a marker of non-speciﬁc absorption. The
molecular size of gliadin and its allergenicity in plasma were examined using immunoblot analysis and
intradermal reaction tests with Evans blue dye (EBD) extravasation, respectively.
Results: Aspirin increased plasma concentrations of gliadin after oral administration but had no effect in
the closed intestinal loop study. An in situ intestinal re-circulating perfusion study showed that
FITC-labeled gliadin was absorbed similarly to FD-40. Aspirin increased absorption of both intact and
pepsin-digested gliadin, with a more signiﬁcant effect on absorption of pepsin-treated gliadin. Immu-
noblotting showed that most gliadin was absorbed in intact form. When the gliadin fraction
was extracted from rat plasma after gavage and injected intradermally into gliadin-sensitized rats, EBD
extravasation was observed at injection sites in a gliadin dose-dependent manner.
Conclusions: Aspirin increased the absorption of intact and pepsin-digested gliadin via the paracellular
pathway, maintaining their allergenicity. Moreover, the effect of aspirin on gliadin absorption was
enhanced by modiﬁcation and digestion of gliadin in the stomach.
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Wheat is a basic staple food all over theworld, but can also cause
food allergies ranging in severity. Severe wheat allergy can result in
life-threatening anaphylaxis. Several clinical types of wheat allergyvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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dermatitis, bakers' asthma, and wheat-dependent exercise-
induced anaphylaxis (WDEIA).1 WDEIA is a speciﬁc type of wheat
allergy that develops after ingestion of wheat products followed
by physical exercise. Patients with WDEIA typically present with
skin manifestations including generalized urticaria, dyspnea and
anaphylactic shock induced by immunoglobulin (Ig) E-mediated
mast cell degranulation.2,3
The total protein content of wheat ﬂour ranges from 8% to 12%,
and wheat proteins can be classiﬁed as water/salt-soluble proteins
(albumin and globulin) and water/salt-insoluble proteins (gluten).4
Gluten is composed of more than two proteins, including those of
the gliadin and glutenin families. Gliadin-family proteins are
monomeric and can be genetically classiﬁed into a/b, g-, u1,2- and
u5-gliadins. The glutenin family proteins are divided into low
molecular weight (LMW)- and high molecular weight (HMW)-
glutenins.4 Gliadin is a major causative allergen of various types of
wheat allergy including WDEIA.1,5e9
Previous reports have demonstrated that the dose of food
allergen absorbed via the intestine is one of the essential factors in
determining the severity of IgE-mediated allergic symptoms.10e12
Since the enzymatic digestibility and intestinal permeability of
allergens may affect their allergenicity, it is important to under-
stand the effects of these factors on allergen absorption and the
pathophysiology of food allergies including WDEIA. Most ingested
proteins including allergens are degraded by gastric and pancre-
atic proteases as well as brush-border proteases in the intestinal
lumen. However, a small amount of intact protein escapes prote-
ase degradation and is absorbed via specialized microfold (M) cells
in Peyer's patches and via transcytosis across epithelial cells
through endocytic and exocytic pathways. Previous reports have
shown that several types of endocytic pathways mediated allergen
absorption, depending on the properties of allergen proteins.13e15
For example, we previously reported that an egg allergen, lyso-
zyme [molecular weight (MW) of 14 kDa and pI of 11] was
absorbed in the proximal intestine via endocytic pathways.13 By
contrast, an egg allergen, ovalbumin (OVA; MWof 45 kDa and pI of
4.7) was preferentially absorbed in the distal intestine via carrier-
mediated endocytic pathways.14 In addition to transcellular path-
ways, intact proteins are absorbed across intestinal epithelial cells
through the paracellular pathway. Although normal enterocytes
form tight junctions, preventing the absorption of macromolecules
through the paracellular pathway, various factors (strenuous
exercise, some drugs, and activation of intestinal mast cells) can
enhance macromolecule permeability following impairment of
tight junctions.16,17
Aspirin is used clinically as an anti-inﬂammatory agent.
However, aspirin elicits and exacerbates allergic symptoms
including anaphylaxis in patients with WDEIA.10,16 Previous re-
ports showed that allergic reactions elicited in provocation tests
in patients with WDEIA were dependent on elevation of serum
gliadin levels after exercise and/or aspirin intake.10,11,16 We pre-
viously reported that aspirin increased intestinal absorption of
intact OVA via the paracellular pathway, resulting in develop-
ment of allergic symptoms in an OVA-sensitized rat model.14,17
These ﬁndings suggested that aspirin-induced facilitation of in-
testinal absorption of allergens could be an underlying mecha-
nism of WDEIA pathogenesis. However, the mechanisms of
gliadin absorption as well as the facilitation of gliadin absorption
by aspirin are poorly understood. In this study, we elucidated
the pathways of gliadin absorption and the effects of aspirin
on gliadin absorption in rat intestine. Furthermore, we also
examined the effects of pepsin digestion since this might affect
gliadin absorption and allergenicity prior to reaching the small
intestine.Methods
Materials
Gliadin was obtained from Tokyo Chemical Industry (TCI, Tokyo,
Japan). Fluorescein isothiocyanate (FITC), FITC-dextran 40 (FD-40;
average MW of 40 kDa), pepsin and Evans blue dye (EBD) were
purchased from SigmaeAldrich (St. Louis, MO, USA). Aspirin was
from Wako Pure Chemicals (Osaka, Japan). Rabbit anti-wheat
gliadin antibody (BYA2520-1) and horseradish peroxidase (HRP)-
conjugated goat anti-rabbit IgG (ALI3404) were obtained from
Accurate Chemical & Scientiﬁc Co. (Westbury, NY, USA) and
BioSource International (Camarillo, CA, USA), respectively. Alum
adjuvant (Imject® Alum) was from Thermo Fisher Scientiﬁc (Wal-
tham, MA, USA). All chemicals were of the highest purity available.
Animals
Male SpragueeDawley (SD) rats aged 7e8 weeks were obtained
from Japan SLC, Inc. (Shizuoka, Japan). Rats were provided with a
standard laboratory diet (MF, Oriental Yeast, Tokyo, Japan) and
water ad libitum. Rats weremaintained in a temperature- and light-
controlled environment formore than 1week prior to experiments.
All experiments involving animals were carried out in accordance
with the Guide for Animal Experimentation from the Committee of
Research Facilities for Laboratory Animal Sciences of Hiroshima
University (approval No. A16-138, Hiroshima, Japan).
Oral administration study
After overnight fasting, SD rats were anesthetized with pento-
barbital (30 mg/kg, i.p.) and cannulated with polyethylene tubing
(PE-50) at the femoral artery for blood sampling. Vehicle alone
[phosphate-buffered saline (PBS), pH 7.4] or vehicle containing
aspirin (30 mg/kg) were administered orally using a stainless-steel
feeding tube. Gliadin (100 mg/kg) suspended in olive oil was
administered orally 30 min after treatment. Blood (0.25 mL) was
collected at designated time intervals for 3 h via the cannula to
determine the plasma concentrations of gliadin. At the end of the
study (3 h), whole bloodwas collected via the abdominal aorta using
a heparinized syringe to evaluate themolecular size and allergenicity
of ingested gliadin circulating in plasma. Each blood sample was
centrifuged and the plasma sample was stored at 30 C until use.
Intestinal closed loop study
After overnight fasting, SD rats were anesthetized with pento-
barbital (30 mg/kg, i.p.) and cannulated with polyethylene tubing
(PE-50) at the femoral artery. The common bile duct was ligated
with surgical sutures. The proximal intestine (a 20-cm long
segment beginning 10 cm below the pylorus) was ﬂushed with
20 mL of saline solution prewarmed to 37 C and ligated to make a
closed loop. Vehicle alone (PBS, pH 7.4) or vehicle containing
aspirin (30 mg/kg) were administered into the closed loop. In our
previous report, pH 6.5 of PBS containing 1% (v/v) dimethyl sulf-
oxide (DMSO) was used to aid the aspirin solubility because the
solubility of aspirin is low at pH 6.5.13 DMSO is often used to
dissolve the water-insoluble compounds, but DMSO may affect the
intestinal absorption of gliadin to disrupt the intestinal barrier
function. Thus, in this study, we used pH 7.4 of PBS without DMSO
to dissolve aspirin. Thirty min later, gliadin (100 mg/kg) suspended
in olive oil was administered into the same loop. Blood (0.25 mL)
was collected at designated time intervals for 1 h via the cannula.
Each blood sample was centrifuged and the plasma sample was
stored at 30 C until use.
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The plasma concentration of gliadin was determined using a
sandwich enzyme-linked immunosorbent assay (ELISA) kit (Mor-
inaga Institute of Biological Science, Yokohama, Japan) according to
the procedure described byMatsuo et al. with slight modiﬁcation.16
The gliadin concentration in each plasma sample was calculated
using known concentrations of gliadin as standards. The detection
limit of gliadin was between 0.78 ng/mL and 50 ng/mL under these
conditions.
Preparation of FITC-labeled gliadin (FITC-gliadin)
Labeling of gliadin with FITC was conducted as described pre-
viously with slight modiﬁcation.13 Brieﬂy, 200 mg gliadin were
dissolved in 0.1 M borate buffer (pH 9.0) containing 50% (v/v)
ethanol and the solutionwas centrifuged at 3000g for 10 min. The
gliadin solution was reacted with 2 mg of FITC dissolved in 0.1 M
borate buffer (pH 9.0) for 2 h at room temperature. After incuba-
tion, the pH was adjusted to 7.5 with 0.1 M boric acid. The mixture
was dialyzed using a cellulose membrane with a molecular-weight
cutoff of 3.5 kDa overnight at 4 C and then concentrated by freeze-
drying. After the lyophilized proteins were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE),
bands corresponding to a/b-, g- and u1,2-gliadins (~30e50 kDa)
were observed after Coomassie brilliant blue (CBB) staining and
imaging with a Fluoroimage Analyzer (Typhoon FLA-7000, GE
Healthcare, Little Chalfont, UK), as reported previously.14
Pepsin digestion of gliadin
Pepsin digestion of FITC-gliadin was performed according to a
previously-described method with slight modiﬁcation.18,19 Brieﬂy,
FITC-gliadin (512 mg/mL in 0.1 M HCl, pH 1.5) was incubated for 1 h
at 37 C with pepsin (417 IU/mg) at an enzyme:substrate ratio of
1:100 (w/w). The digestion was terminated by addition of 1 M
NaOH solution at designated time intervals for 1 h. Digestion of
FITC-gliadin was conﬁrmed using Fluoroimage Analyzer FLA-7000
after electrophoretic separation by SDS-PAGE in the same manner
as for intact FITC-gliadin. For the in situ re-circulating perfusion
experiment, we used FITC-gliadin digested with pepsin for 0.75 h.
Digested FITC-gliadin was lyophilized and stored at 30 C
until use.
In situ re-circulating perfusion study
Intestinal absorption of intact and pepsin-digested FITC-gliadin
was evaluated in a re-circulating perfusion experiment as described
previously, with slight modiﬁcations.13 Brieﬂy, after overnight
fasting, SD rats were anesthetized with pentobarbital (30 mg/kg,
i.p. injection) and afﬁxed supine under an incandescent lamp to
maintain their body temperatures around 36 C. The common bile
duct was ligated with ligating string. The proximal intestine (a 20-
cm long segment beginning 10 cm below the pylorus) was ﬂushed
with saline solution prewarmed to 37 C and a loop was con-
structed. The intestinal segment was pre-perfusedwith PBS, pH 6.5,
warmed at 37 C for 15 min, then perfused by re-circulation of
10 mL of PBS containing intact or pepsin-digested FITC-gliadin
(12.8 mg/mL) at 2 mL/min. To examine the effects of aspirin, aspirin
(3 mg/mL) was added to the perfusate. Intestinal perfusate samples
(100 mL) were collected periodically and mixed with 0.25 M NaOH
solution (100 mL) to determine FITC-gliadin concentration. The
absorption of FD-40 (0.4 mM) was estimated in the same way as for
FITC-gliadin. Concentrations of FITC-gliadin and FD-40 in perfusate
were determined at a wavelength of 500 nm for excitation and520 nm for emission using a Microplate Fluorometer (PerkinElmer,
Waltham, MA, USA). Stability of FITC-gliadin in perfusate was
evaluated using Fluoroimage Analyzer FLA-7000 after separation
by SDS-PAGE as reported previously.14
Immunoblot analysis of plasma gliadin after oral administration
Immunoblot analysis of ingested gliadin circulating in plasma
was performed as described previously with slight modiﬁcation.9,20
Brieﬂy, 2.5 mL of plasma was mixed with 0.5 mL of distilled water
and 7 mL of absolute ethanol. After vortex mixing for 1 min, the
mixture was centrifuged at 20,000 g for 5 min at 20 C. The su-
pernatant was transferred to a new tube and evaporated. The res-
idue was dissolved in 0.1 mL of gel loading buffer containing 5% (w/
v) 2-mercaptoethanol. Samples (15 mL) were applied to each lane of
a 12.5% polyacrylamide gel. Western blot analysis was performed
using an anti-gliadin antibody (diluted 1:1000) followed by a
HRP-conjugated anti-rabbit IgG (diluted 1:30,000). The blots were
developed using a chemiluminescent substrate (Western Light-
ning®Ultra, PerkinElmer, Waltham, MA, USA) and imaged using a
LAS-4000 mini instrument (GE Healthcare, Little Chalfont, UK) as
reported previously.9
Evaluation of gliadin allergenicity in plasma after oral
administration
To evaluate the allergenicity of circulating gliadin in plasma,
intradermal reaction tests were performed using the EBD extrava-
sation method in a gliadin-sensitized rat model as described pre-
viously with slight modiﬁcation.17 Brieﬂy, rats were sensitized by
intraperitoneal injectionwith 1 mL of physiologic saline containing
5 mM acetic acid, 1 mg of gliadin and Imject® Alum [10 mg Al(OH)3
and 10 mg Mg(OH)2] at weekly intervals for 6 weeks. Six weeks
after the ﬁrst immunization, blood (0.2 mL) was collected from the
jugular vein to assess plasma levels of gliadin-speciﬁc IgE by ELISA.
Rats with high gliadin-speciﬁc IgE titers were used in this study.
Plasma levels of gliadin-speciﬁc IgE (absorbance at 450 nm) prior to
gliadin sensitization and 6 weeks after the ﬁrst gliadin immuni-
zationwere 0.00 ± 0.00 and 0.06 ± 0.01, respectively. The fur on the
backs of these rats was shaved using an electric clipper (Thrive
2100; Daito Electric Machine Industry, Osaka, Japan). Twenty-four
h after shaving, rats with no wounds were anesthetized with
pentobarbital (30 mg/kg, i.p.), and cannulated with polyethylene
tubing (PE-50) at the femoral vein. Gliadin was spiked into rat
plasma containing no gliadin at a concentration of 150 ng/mL.
Reference and ingested gliadin were extracted from plasma (30 mL)
as described for immunoblot analyses. After evaporation, the
residue was dissolved in 150 mL of 17.5 mM acetic acid. Rats were
injected intradermally with 100 mL of each gliadin sample. Thirty
min later, EBD (5mg) was injected intravenously via the cannula. As
a positive control, histamine dissolved in 100 mL of physiologic
saline (150 mg/mL) was simultaneously injected intradermally.
Thirty min later, the skin was stripped and photographed. The
injected sites were punch-biopsied using a dermal punch for EBD
quantitation. Each skin sample (0.1 g) was immersed in formamide
(5 mL) to extract EBD at 20 C for 24 h. Another skin sample (0.1 g)
was dried at 60 C for 24 h. The concentration of EBD was deter-
mined at a wavelength of 620 nm using Multiskan GO (Thermo
Fisher Scientiﬁc) and represented as mg/g dry tissue weight.
Statistical analyses
Datawere displayed as the means ± standard errors of the mean
(S.E.). Mean value differences between groups were assessed using
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Student's t-tests. P < 0.05 was considered statistically signiﬁcant.
Results
Effect of aspirin on gliadin absorption after oral and intra-intestinal
loop administration
The effects of aspirin on plasma gliadin concentrations were
evaluated after oral and intra-intestinal loop administration in SD
rats. When gliadin was administered orally, it was absorbed into
blood gradually over time and reached a peak plasma concentra-
tion (Cmax) of 3.23 ± 0.99 ng/mL 1 h after gavage (Fig. 1A). Aspirin
signiﬁcantly increased the gliadin Cmax and the area under the
concentrationetime curve from 0 to 3 h (AUC0e3 h) by ~8.6-fold
(3.23 ± 0.99 ng/mL vs 27.7 ± 7.96 ng/mL, P < 0.05) and ~11.3-fold
(5.15 ± 0.47 ng-h/mL vs 58.0 ± 16.2 ng-h/mL, P < 0.05), respec-
tively. By contrast, when gliadin was administered into the
intestinal loop, Cmax reached 18.5 ± 8.75 ng/mL 10 min after
administration (Fig. 1B). In the intestinal loop study, aspirin did not
affect plasma concentrations (or AUC0e3 h) of gliadin.
Pepsin digestion of gliadin
Hydrolysis of gliadin by pepsin was evaluated by SDS-PAGE
(Fig. 2). Bands corresponding to the molecular sizes of a/b-, g-,
and u1,2-gliadins (30e50 kDa) were observed in reagent gliadin in
the presence or absence of pepsin, but u5-gliadin (~60 kDa) was
not observed. In our preliminary study, we also could not obtain the
clear band of u5-gliadin by western blot analysis using anti-gliadin
antibody. Thus, the content of u5-gliadin may be much lower than
those of the other gliadin in reagent gliadin. The electrophoretic
proﬁles of gliadin showed no changes during incubation in the
absence of pepsin. By contrast, gliadin was gradually hydrolyzed
over time by pepsin into peptides with MWs of ~25 kDa and
completely degraded into peptides after 0.75 h. Thus, we used FITC-
gliadin digested with pepsin for 0.75 h in an in situ re-circulating
perfusion experiment.Fig. 1. Effect of aspirin on plasma concentrations of gliadin after oral (A) and intra-
intestinal loop (B) administration in SD rats. Aspirin (30 mg/kg) was administered
30 min before oral or intra-intestinal loop administration of gliadin at a dose of
100 mg/kg. Open and closed circles represent the control (vehicle alone) and aspirin
treatment, respectively. Each value represents the mean ± S.E. of ﬁve (A) and seven (B)
rats. *P < 0.05 with respect to control. In these studies, two rats, a control rat and an
aspirin treatment rat, were evaluated simultaneously. The oral (A) and intra-intestinal
loop (B) administration studies were independently performed ﬁve and seven times,
respectively and we conﬁrmed the results were almost same among these indepen-
dent trials.Absorption of intact and pepsin-digested FITC-gliadin in rat
intestine and effect of aspirin on gliadin absorption
To investigate the absorption pathways of intact and pepsin-
treated gliadin as well as the effect of aspirin on absorption, we
performed an in situ re-circulating perfusion study. Approximately
20% of the initial dose of intact FITC-gliadin was absorbed from
perfusate 1.5 h after initiation of perfusion, similar to absorption of
FD-40, a marker for non-speciﬁc absorption through paracellular
pathways (Fig. 3A). Aspirin increased absorption of intact
FITC-gliadin by ~1.7-fold. These results suggested that aspirin
enhanced intestinal gliadin absorption through the paracellular
pathway. In perfusate samples obtained 1.5 h after initiation of
perfusion, intact FITC-gliadin was observed by SDS-PAGE analysis
(data not shown). Thus, FITC-gliadin might be absorbed from the
intestinal perfusate over the time course of the perfusion. Next, we
examined the intestinal absorption of pepsin-digested gliadin
and the effect of aspirin on absorption using the same perfusion
method. When pepsin-digested FITC-gliadin was perfused into the
rat intestinal lumen, ~20% of the initial dose was absorbed 1.5 h
after imitation of perfusion. Aspirin increased intestinal absorption
of pepsin-digested FITC-gliadin by ~2.5-fold (Fig. 3B). Thus, pepsin
digestion enhanced the aspirin-induced absorption of gliadin.
Molecular sizes of gliadin absorbed into plasma after oral
administration
To determine the molecular sizes of ingested gliadin, we
extracted gliadin from plasma with 70% ethanol 3 h after oral
administration and then evaluated their sizes by western blot
analysis (Fig. 4). In reagent gliadin, bands of ~35e45 kDa, corre-
sponding to a/b-, g-, and u1,2-gliadins were observed but
u5-gliadin (~60 kDa) was not observed. Bands of ~35e45 kDa were
also detected in plasma samples containing 17.1 and 47.1 ng/mL
gliadin. Furthermore, LMW bands (<35 kDa) and HMW bands
(64 kDa) were detected in these plasma samples. These results
suggested that gliadin can be absorbed in intact form, although
some types of gliadin were degraded by enzymes in the intestinal
lumen and tissues.
Allergenicity of gliadin absorbed into plasma after oral
administration
To evaluate the allergenicity of gliadin absorbed into plasma, an
intradermal reaction test was performed using the EBD extrava-
sation method (Fig. 5). When histamine was injected intradermally
into gliadin-sensitized rats, extravasation of EBD was observed.
When gliadin extracted from the plasma of rats after ingestion was
injected intradermally into gliadin-sensitized rats, EBD extravasa-
tion was observed. Thus, we conﬁrmed that this rat model is
suitable to assess the allergenicity of gliadin. The extent of EBD
extravasation depended on plasma gliadin concentration. By
contrast, the extracted material from plasma containing no gliadin
did not induce EBD extravasation. These results indicated that
gliadin with allergenic activity was absorbed from the intestine.
Discussion
The amount of allergen absorbed into blood is a key factor in
determining the development and severity of food-dependent
exercise-induced anaphylaxis (FDEIA) symptoms. Thus, it is
important to elucidate the mechanisms of intestinal absorption of
allergens, as well as the effects of agents that disrupt intestinal
homeostasis, to understand the pathophysiology of FDEIA. In this
study, we characterized the mechanisms of gliadin absorption
Fig. 2. SDS-PAGE analysis of pepsin-digested gliadin. FITC-gliadin was incubated for 1 h at 37 C in the absence [pepsin ()] or presence [pepsin (þ)] of pepsin under acidic
conditions (pH 1.5). FITC-gliadin was detected using a Fluoroimage Analyzer FLA-7000 after separation by SDS-PAGE. This trial was repeated three times independently to conﬁrm
the reproducibility.
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digestion on aspirin-facilitated absorption of gliadin in rat intestine.
When gliadin was administered orally to aspirin-treated rats,
plasma concentrations of gliadin were signiﬁcantly higher than
those in vehicle-treated controls (Fig.1). This result agreed with our
previous ﬁnding that aspirin enhanced absorption of ingested
gliadin in healthy human volunteers.16 In this study, we adminis-
tered gliadin at a dose of 100 mg/kg. According to the Food and
Drug Administration (FDA), dose of compounds in rats should be
divided by coefﬁcient factor (6.2) to convert to human equivalent
dose based on the body surface area.21 Thus, a 100 mg/kg dose ofFig. 3. Effect of aspirin on intestinal absorption of intact (A) or pepsin-digested (B)
FITC-gliadin in the in situ re-circulating perfusion study. The amount of FITC-gliadin
absorbed was assumed to be equivalent to the amount eliminated from perfusate.
The concentration of aspirin in the perfusate was 3 mg/mL. Open and closed circles
represent the control (vehicle alone) and aspirin treatment, respectively. Open tri-
angles represent absorption of FD-40. Each value represents the mean ± S.E. of four
rats. *P < 0.05 and **P < 0.01 with respect to control. yP < 0.01 with respect to intact
FITC-gliadin. In the re-circulating perfusion study, ﬁve rats, a control and an aspirin
treatment rat for intact FITC-gliadin (A), a control and an aspirin treatment rat for
pepsin-digested FITC-gliadin (B), and a rat for FD-40, were evaluated simultaneously.
This experiment was independently performed four times and we conﬁrmed results
were almost same among these independent trials.gliadin in rats corresponds to 16.1 mg/kg in humans. Since wheat
ﬂour is composed of ~6% gliadin, we estimate that the dosage of
gliadin used in this study corresponds roughly to ~0.27 g/kg of
wheat ﬂour in humans.22 In wheat challenge tests, the mass of
ingested wheat ﬂour is typically ~70e135 g.16 In addition, the
dosage of aspirin used in this study (30 mg/kg) was estimated to be
equivalent to ~4.8 mg/kg in humans.21 In clinical settings, aspirin is
used as an anti-inﬂammatory drug at a dose of 0.5e1.5 g. Assuming
human bodyweight is ~50 kg, clinical dose of aspirin is estimated to
10e30 mg/kg which corresponds to 62e186 mg/kg in rats. Thus,
the dosages of gliadin and aspirin used in this study may have been
smaller than those used clinically, but not signiﬁcantly so.
Aspirin did not increase gliadin absorption after intra-intestinal
loop administration while it did so after gavage. The reason un-
derlying the difference in aspirin facilitation of gliadin absorptionFig. 4. Western blot analysis of gliadin circulating in plasma after oral administration
in rats. Aspirin (30 mg/kg) was administered 30 min before oral administration of
gliadin at a dose of 100 mg/kg (Gliadin in plasma). The sample “0” was obtained from
one rat administered with aspirin and olive oil (vehicle for gliadin). Each plasma
sample was collected from one (individual) rat used in the four independent oral
administration studies. As a reference, gliadin was spiked into rat plasma containing no
gliadin at a concentration of 150 ng/mL (Reagent gliadin). Gliadin was extracted with
70% ethanol from plasma 3 h after oral gliadin administration. Each gliadin sample was
separated by 12.5% SDS-PAGE and blotted onto a PVDF membrane. The membrane was
incubated with anti-gliadin antibody. Plasma concentrations of gliadin were deter-
mined by ELISA. Western blot analysis was repeated three times independently to
conﬁrm the molecular sizes of ingested gliadin.
Fig. 5. Allergenicity of gliadin circulating in plasma after oral administration in rats. Aspirin (30 mg/kg) was administered 30 min before oral administration of gliadin at a dose of
100 mg/kg (Gliadin in plasma). The sample “0” was obtained from one rat administered with aspirin and olive oil (vehicle for gliadin). Each plasma sample was collected from
individual rat used in the three independent oral administration studies. As a reference, gliadin was spiked into rat plasma containing no gliadin at a concentration of 150 ng/mL
(Reagent gliadin). Gliadin was extracted with 70% ethanol from plasma 3 h after oral gliadin administration. Reagent gliadin was spiked into rat plasma containing no gliadin at a
concentration of 150 ng/mL. As a positive control, 100 mL of histamine dissolved in physiologic saline (150 mg/mL) was simultaneously injected intradermally. Intradermal reaction
test was repeated three times independently to conﬁrm the allergenicity. ND represents the value which bellows the detection limit (concentration of Evans blue dye: 1.78 mg/mL) in
the assay.
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possible hypotheses may explain this ﬁnding. First, gliadinmight be
modiﬁed by acid in the stomach. Gliadin is a water/salt-insoluble
protein and its solubility in water was reportedly ~0.3 mg/mL.18
In our intestinal loop study, plasma concentrations of gliadin
displayed ﬂip-ﬂop kinetics, indicating that the elimination rate was
greater than the absorption rate due to the poor solubility of gliadin
(Fig. 1). Furthermore, aspirin increased the intestinal absorption
of FITC-gliadin dissolved at a much lower concentration in an in situ
re-circulating study, unless gliadin did not pass through the
stomach (Fig. 3). Gliadin contains a large number of glutamine
residues that can be easily deamidated to glutamic acid by acidic
hydrolysis. Kumagai et al. reported that the solubility of deamidated
gliadin was ~1.6-fold higher in water than that of unmodiﬁed
gliadin.18 Thus, the solubility of gliadin may be related to its oral
absorption and thus to the effect of aspirin. Second, gliadin might
be degraded by acid and pepsin in the stomach. Our perfusion study
showed that aspirin increased the intestinal absorption of pepsin-
digested FITC-gliadin (~25 kDa) by ~2.5-fold and that of intact
FITC-gliadin (~30e50 kDa) by~1.7-fold (Fig. 3). These results sug-
gest that degradation of gliadin by pepsin enhances the aspirin-
facilitated absorption of gliadin. However, we also showed that
more than 0.5-h digestion with pepsin was needed for degradation
of gliadin into peptides (Fig. 2). Mori et al. reported that the re-
covery of FD-10S from the stomachs of fasting rats was ~20% of the
initial dose 0.5 h after oral administration as a powder.23 These
results suggest that most gliadin may be excreted from the stomach
before pepsin digestion. In general, wheat is eaten after heating,
and heating may affect the digestibility of gliadin by pepsin.
However, we did not examine the effect of heating on gliadin
digestion by pepsin in this study. Further studies are necessary to
clarify the role of acid and pepsin in modiﬁcation and degradation
of gliadin in the stomach using unheated and heated gliadin. In
addition to pepsin digestion, gliadin is reportedly digested by
pancreatin, containing trypsin and chymotrypsin.18 However, the
effects of pancreatin digestion can be disregarded since the
digestibility of gliadin by pancreatin is minimal compared with
pepsin. Therefore, we surmise that the effects of degradation by
digestive enzymes on aspirin-facilitated absorption of gliadin after
oral administration are negligible. In fact, our results showed that
most gliadin was absorbed into blood from the intestinal lumen in
intact form retaining its allergenicity, despite the fact that some
gliadin was degraded (Fig. 4, 5).
In immunoblot analysis, binding of anti-gliadin antibody to
HMW proteins (65 kDa) was observed for samples containing
high gliadin content (Fig. 4). The identities of HMW proteins werenot assessed in this study. Previous reports have shown that
gliadin-gliadin complexes with HMWs were formed as a result of
cross-linking by tissue transglutaminase (t-TG) in the intestine.24,25
We speculate that HMW species can result from rearrangement of
intact and/or degraded gliadins due to cross-linking between a
lysine residue and a glutamine residue by t-TG. In the perfusion
study, we used FITC-labeled gliadin. Because FITC is bound to lysine
residues in gliadin, it is considered that FITC labeling may inhibit
the formation of rearranged HMW gliadins during the perfusion.
Further studies are necessary to clarify the effect of FITC labeling on
the rearrangement of HMW gliadins.
Intact FITC-gliadin was absorbed from perfusate to the same
extent as FD-40, indicating that gliadin was absorbed through the
paracellular pathway (Fig. 3A). We previously reported that aspirin
enhanced the intestinal absorption of FDs with different molecular
weights (FD-10, average MW of 9.4 kDa; FD-150, average MW of
167 kDa), without affecting intestinal accumulation, by impairment
of enterocytic tight junctions.13 Moreover, we reported that aspirin
increased the oral absorption of FD-40 by ~2.0-fold compared with
that in controls.17 These reports suggested that aspirin induced
gliadin absorption through the paracellular pathway following
disruption of the intestinal barrier by suppression of prostaglandin
synthesis by cyclooxygenase (COX)-1,26 oxidative stress27 and
modulation of tight junctional proteins such as zonula occludens
(ZO)-128 and claudin-7.29 In addition, Hamarneh et al. reported that
loss of intestinal alkaline phosphatase (IAP) expression increased
intestinal permeability to FD-4 and FD-10 via impaired intestinal
barrier function.30 Kaur et al. reported that aspirin decreased IAP
activity.31 Taking into account all of these results, aspirin may
promote absorption via the paracellular pathway by impairment of
intestinal barrier function due to inhibition of IAP activity.
When plasma sample containing gliadin was injected intrader-
mally into gliadin-sensitized rats, gliadin caused EBD extravasation
in a dose-dependent manner (Fig. 5). However, the amount of EBD
extravasation by injection of plasma containing 47.1 ng/mL of
gliadin was higher than that by injection of reagent gliadin spiked
into plasma at concentration of 150 ng/mL. The reason why the
amount of EBD extravasation did not depend on the dose of gliadin
between plasma sample and reagent is not clear at present. We
speculate that speciﬁc IgE antibodies to modiﬁed gliadin may be
produced in gliadin-sensitized rats and these IgE may react with
modiﬁed gliadin in plasma sample. Further studies are necessary to
clarify the difference in IgE reactivity between ingested (modiﬁed)
and reagent (intact) gliadins.
In conclusion, we showed that aspirin increased absorption of
intact and pepsin-digested gliadin via the paracellular pathway
T. Yokooji et al. / Allergology International 68 (2019) 247e253 253while maintaining its allergenicity. Furthermore, the effect of
aspirin on gliadin absorptionwas enhanced by gliadin modiﬁcation
and pepsin digestion in the stomach. Thus, oral absorption of
gliadin may be modulated by various factors such as drugs and
meals which alter gastric emptying rate, stomach pH and gliadin
solubility. These ﬁndings shed new light on the pathophysiological
mechanisms underlying WDEIA.Acknowledgments
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